logo-loader

RXi Pharmaceuticals gene therapy gets patent boost

Last updated: 09:10 19 Apr 2016 EDT, First published: 04:10 19 Apr 2016 EDT

shutterstock_327930476
Once issued, the patent will last until 2031.

RXi Pharmaceuticals Corp (NASDAQ:RXII) told investors it has fortified its patent portfolio for its novel RNAi gene therapies.

The company said that it has received a notice of allowance, from the United States Patent and Trademark Office (USPTO) regarding the composition of matter and methods of use for its self-delivering RNAi compounds targeting connective tissue growth factor (CTGF).

The patent includes RXi’s lead clinical candidate, called RXI-109, which is currently being evaluated in multiple clinical trials.

Once issued, the patent will last until 2031.

Dr Geert Cauwenbergh, chief executive, said: "We are pleased to have be granted this Notice of Allowance from the USPTO.

"This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications, such as liver fibrosis."

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

58 minutes ago